29608-05-7

Basic information

• Product Name: 4-PIPERIDIN-1-YLMETHYL-PHENYLAMINE
• Synonyms: TIMTEC-BB SBB007056;4-(PIPERIDIN-1-YLMETHYL)ANILINE;4-PIPERIDIN-1-YLMETHYL-PHENYLAMINE;4-(1-PIPERIDINYLMETHYL)ANILINE;AKOS MSC-0180;AKOS B014375;ART-CHEM-BB B016020;ART-CHEM-BB B014375
• CAS NO: 29608-05-7
• Molecular Formula: C₁₂H₁₈N₂
• Molecular Weight: 190.28
• EINECS: 1312995-182-4
• Product Categories: Amines and Anilines;Piperidine;Heterocyclic Compounds
• Mol File: 29608-05-7.mol

Chemical Properties

• Melting Point: 90-93
• Boiling Point: 308.694 °C at 760 mmHg
• Flash Point: 126.388 °C
• Appearance: /
• Density: 1.068 g/cm³
• Vapor Pressure: 0.000794mmHg at 25°C
• Refractive Index: 1.555
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9?+-.0.10(Predicted)
• Water Solubility: immiscible
• CAS DataBase Reference: 4-PIPERIDIN-1-YLMETHYL-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PIPERIDIN-1-YLMETHYL-PHENYLAMINE(29608-05-7)
• EPA Substance Registry System: 4-PIPERIDIN-1-YLMETHYL-PHENYLAMINE(29608-05-7)

Safety Data

• Hazard Codes: C
• Statements: R36/37/38:
• Safety Statements: S26:; S36:
• Hazardous Substances Data: 29608-05-7(Hazardous Substances Data)

Usage

Uses

Since the provided materials do not specify the uses of 4-Piperidin-1-ylmethyl-phenylamine, it is not possible to list its applications based on the given information. However, if future research or data becomes available, it may be possible to identify specific applications for this compound in various industries.

InChI:InChI=1/C12H18N2/c1-2-4-11(5-3-1)10-14-12-6-8-13-9-7-12/h1-5,12-14H,6-10H2

Upstream product

• 59507-44-7 1-(4-nitrobenzyl)piperidine 
• 110-89-4 piperidine 
• 555-16-8 4-nitrobenzaldehdye 
• 100-14-1 4-nitrobenzyl chloride 
• 100-11-8 1-bromomethyl-4-nitro-benzene 

Downstream Products

• 108176-89-2 2-[(4-Piperidin-1-ylmethyl-phenylamino)-methyl]-isoindole-1,3-dione 
• 108176-83-6 3-<4-(N-piperidinomethyl)phenylaminomethyl>benzoxazolin-2-one 
• 108176-92-7 1,3-bis<4-(N-piperidinomethyl)phenylaminomethyl>benzimidazoline-2-thione 
• 108176-86-9 6-chloro-3-<4-(N-piperidinomethyl)phenylaminomethyl>benzoxazolin-2-one 
• 229003-39-8 7-phenyl-N-[4-(piperidinomethyl)phenyl]-3,4-dihydronaphthalene-2-carboxamide 
• 229003-49-0 7-(4-methylphenyl)-N-[4-(piperidinomethyl)phenyl]-3,4-dihydronaphthalene-2-carboxamide 
• 229005-30-5 N-[4-(1-piperidinylmethyl)phenyl]-6-(4-methylphenyl)-2H-1-benzopyran-3-carboxamide 
• 229004-30-2 7-(4-methylphenyl)-N-(4-(piperidinomethyl)phenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide 
• 229004-26-6 2-[(4-methyl)phenyl]-N-{4-[(piperidin-1-yl)methyl]phenyl}-6,7-dihydro-5H-benzo[7]annulene-8-carboxamide 
• 263339-14-6 (Z)-6-nitro-3-[phenyl-(4-piperidin-1-ylmethyl-phenylamino)methylene]-indolin-2-one 
• 689299-71-6 (E)-3-(4'-chloro-biphenyl-4-yl)-N-(4-piperidin-1-ylmethyl-phenyl)-acrylamide 
• 503183-23-1 4-[(4-(piperidin-1-ylmethyl)-phenyl)hydrazono]-4H-pyrazole-3,5-diamine 
• 422518-00-1 (Z)-1-acetyl-5-nitro-3-(phenyl(4-(piperidin-1-ylmethyl)phenylamino)methylene)-indolin-2-one 
• 307302-06-3 N-[4-(piperidinomethyl)phenyl]-7-phenyl-1,2,3,4-tetrahydronaphthalene-2-carboxamide 

Relevant articles and documents

Synthesis of the Kinase Inhibitors Nintedanib, Hesperadin, and Their Analogues Using the Eschenmoser Coupling Reaction

A novel synthetic approach involving an Eschenmoser coupling reaction of substituted 3-bromooxindoles (H, 6-Cl, 6-COOMe, 5-NO2) with two substituted thiobenzanilides in dimethylformamide or acetonitrile was used for the synthesis of eight kinase inhibitor

Synthesis, β-hematin inhibition studies and antimalarial evaluation of new dehydroxy isoquine derivatives against Plasmodium berghei: A promising antimalarial agent

Many people are affected by Malaria around the world, and the parasite is developing resistance against available drugs. Currently, isoquine and N-tert-butyl isoquine are some of the most promising antimalarial candidates that have already reached Phase I

Beta-carboline derivative targeted to CDK and DNA and preparation method and medical application thereof

The invention discloses a beta-carboline derivative targeted to CDK and DNA and a preparation method and medical application thereof. The beta-carboline derivative has a structure shown in the general formula I in the description. The compound can be applied in combination with other antitumor drugs and can also be applied in combination with radiotherapy. The antitumor drugs or radiotherapy and the compound can be applied at the same time or at different times. The combined therapy can perform a synergistic effect, and thus the therapeutic effect can be easily improved.

Quinoline derivatives and their use

The invention discloses a quinoline derivative and a usage thereof, a compound with a structure as shown in a formula (I) and or a pharmaceutically acceptable salt of the compound. The compound or the pharmaceutically acceptable salt thereof disclosed by the invention can be applied to the field of preparation of drugs for preventing or treating tumors.

Discovery of Selective Inhibitors Targeting Acetylcholinesterase 1 from Disease-Transmitting Mosquitoes

Vector control of disease-transmitting mosquitoes is increasingly important due to the re-emergence and spread of infections such as malaria and dengue. We have conducted a high throughput screen (HTS) of 17,500 compounds for inhibition of the essential AChE1 enzymes from the mosquitoes Anopheles gambiae and Aedes aegypti. In a differential HTS analysis including the human AChE, several structurally diverse, potent, and selective noncovalent AChE1 inhibitors were discovered. For example, a phenoxyacetamide-based inhibitor was identified with a 100-fold selectivity for the mosquito over the human enzyme. The compound also inhibited a resistance conferring mutant of AChE1. Structure-selectivity relationships could be proposed based on the enzymes' 3D structures; the hits' selectivity profiles appear to be linked to differences in two loops that affect the structure of the entire active site. Noncovalent inhibitors of AChE1, such as the ones presented here, provide valuable starting points toward insecticides and are complementary to existing and new covalent inhibitors.

Hydrogenation of (N,N-disubstituted aminomethyl)nitrobenzenes to (N,N-disubstituted aminomethyl)anilines catalyzed by palladium-nickel bimetallic nanoparticles

Since palladium-catalysts have strong abilities for both hydrogenation of nitro-group and hydrogenolysis of benzylamine, they have a much lower chemoselectivity for the hydrogenation of (N,N-disubstituted aminomethyl)nitrobenzenes. In this article, component stable Pd-Ni bimetallic nanoparticles were prepared by simply heating RANEY-Ni and Na2PdCl4 together in water. They demonstrated novel synergistic effects when they were used as a bimetallic catalyst, by which a highly efficient and chemoselective hydrogenation of (N,N-disubstituted aminomethyl)nitrobenzenes to (N,N-disubstituted aminomethyl)anilines was achieved.

Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease

A series of ebselen derivatives were designed, synthesised and evaluated as inhibitors of cholinesterases (ChEs) and glutathione peroxidase (GPx) mimics. Most of the compounds were found to be potent against AChEs and BuChE, compounds 5e and 5i, proved to be the most potent against AChE with IC50 values of 0.76 and 0.46 μM, respectively. Among these hybrids, most of the compounds were found to be good GPx mimics compare with ebselen. The selected compounds 5e and 5i were also used to determine the catalytic parameters and in vitro hydrogen peroxide scavenging activity. The results indicate that compounds 5e and 5i may be excellent multifunctional agents for the treatment of AD.

Design and synthesis of novel 3-substituted-indole derivatives as selective H3 receptor antagonists and potent free radical scavengers

A series of novel 3-substituted-indole derivatives with a benzyl tertiary amino moiety were designed, synthesized and evaluated as H3 receptor antagonists and free radical scavengers for Alzheimer's disease therapy. Most of these synthesized co

Discovery and structure-activity relationships of pyrrolone antimalarials

In the pursuit of new antimalarial leads, a phenotypic screening of various commercially sourced compound libraries was undertaken by the World Health Organisation Programme for Research and Training in Tropical Diseases (WHO-TDR). We report here the detailed characterization of one of the hits from this process, TDR32750 (8a), which showed potent activity against Plasmodium falciparum K1 (EC50 ～ 9 nM), good selectivity (>2000-fold) compared to a mammalian cell line (L6), and significant activity against a rodent model of malaria when administered intraperitoneally. Structure-activity relationship studies have indicated ways in which the molecule could be optimized. This compound represents an exciting start point for a drug discovery program for the development of a novel antimalarial.

Anti-prion activities and drug-like potential of functionalized quinacrine analogs with basic phenyl residues at the 9-amino position

In this paper, we report the synthesis and cell-based anti-prion activity of quinacrine analogs derived by replacing the basic alkyl side chain of quinacrine with 4-(4-methylpiperazin-I-yl)phenyl, (1-benzylpiperidin-4-yl) and their structural variants. Several promising analogs were found that have a more favorable anti-prion profile than quinacrine in terms of potency and activity across different prion-infected murine cell models. They also exhibited greater binding affinities for a human prion protein fragment (hPrP121-231) than quinacrine, and had permeabilities on the PAMPA-BBB assay that fall within the range of CNS permeant candidates. When evaluated on bidirectional assays on a Pgp overexpressing cell line, one analog was less susceptible to Pgp efflux activity compared to quinacrine. Taken together, the results point to an important role for the substituted 9-amino side chain attached to the acridine, tetrahydroacridine and quinoline scaffolds. The nature of this side chain influenced cell-based potency, PAMPA permeability and binding affinity to hPrP121-231.